Business
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
Expects U.S. Approval Within 90 Days for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels Provides 2025 Guidance and Maintains Projection
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\nExpects U.S. Approval Within 90 Days for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels\n\n\nProvides 2025 Guidance and Maintains Projection for Full-Year 2025 Profitability1\n\n\n\nPreliminary Unaudited Net Revenue of $79.0 Million for the Fourth Quarter 2024, Representing 30% Growth Over the Prior Year\n\n\n\nPreliminary Unaudited Net Revenue of $266.3 Million for the Full-Year 2024, Representing 32% Growth Over the Prior Year and at the Top of the Company’s Guidance\n\n\n\nExpects U.S. Food and Drug Administration (FDA) Approval Within 90 Days for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid (HA) Gels; U.S. Launch Planned for Q2 2025, A Full Quarter Ahead of Prior Timeline\n\n\n\n2025 Net Revenue Guidance of $345 Million to $355 Million, Which Represents 30% to 33% Growth from Preliminary 2024 Results; Evolysse™ and Estyme® Injectable HA Gels Anticipated to Contribute 8-10% of Total Revenue for the Full-Year 2025\n\n\n\n2025 Non-GAAP Operating Expenses Expected to be $230 Million to $240 Million, with Expected Profitability1 for the Full-Year 2025\n\n\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company’s 2024 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2024, which is anticipated to occur in early March 2025.\n\n\n“The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau® and international expansion of Nuceiva®,” said David Moatazedi, President and Chief Executive Officer of Evolus. “We exceeded 30% revenue growth for the fifth consecutive year, delivering results at multiples above the market, further validating our performance beauty approach and the effectiveness of our business model. These record results, at the top of our guidance, ma...